Abstract
Results of the Hermine study of trastuzumab beyond progression in breast cancer patients, published by Extra and colleagues in The Oncologist, are re-examined and an alternative explanation for the dismal postprogression survival time of patients stopping therapy is presented.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / mortality
-
Prognosis
-
Retrospective Studies
-
Survival Rate
-
Trastuzumab
-
Treatment Outcome
-
Withholding Treatment
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Trastuzumab